DERM · Journey Medical Corp
$7.47
-0.06 (-0.80%)
At close · Aug 28
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, as a result of recurring and historical losses, substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$210.84M
Shares
28.22M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.47
Open$7.56
Day$7.38–7.60
52W close$4.39–9.26
Avg vol 30d205K
Short int2.9M · 10.3% float · 10.4d
Short vol57%
Last earningsAug 12, 2026
DataNov 2021–Aug 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 12, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
+10%
above
RSI (14)
61
neutral
MACD trend
Positive
52-week position
63%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+17%
trailing
6-month return
−7%
trailing
YTD return
−3%
this year
Relative strength
−20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.34% of float · ▲ +1.5% MoM · 10.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
71 holders — mid 3-yr range
Squeeze score
81
high risk · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
EPS growth
+35%
Y/Y
Balance sheet
$1.2M
net debt
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2023
SG&A reductions
· when compared to 2022
at least $12M
Prior guidance
period ended
· from the 8-K filed Feb 5, 2025
Net product revenue
· full year ended December 31, 2024
$55M – $60M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
61
Neutral
MACD trend
Positive
Bullish
52-week position
63%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.34% of float · ▲ +1.5% MoM · 10.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
71 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $7 · 63%
Range high $9
vs 200-day avg +7%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Emrosi® total prescriptions (TRx) | 36,000 | second quarter of 2026 | — |
| Non-GAAP Adjusted EBITDA non-GAAP | $3.49M | Six-Month Periods Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP EBITDA 1.42M
+1.44M Share-based compensation
+1K Foreign exchange transaction losses
= Non-GAAP Adjusted EBITDA 2.86M
|
|||
| Non-GAAP Adjusted EBITDA per common share - Basic non-GAAP | $0.13 | Six-Month Periods Ended June 30, 2026 | — |
| Non-GAAP Adjusted EBITDA per share non-GAAP | $0.1 | Three-Month Periods Ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | $0.6M | first quarter of 2026 | — |
| EBITDA non-GAAP | -$369K | Three-Month Periods Ended March 31, 2026 | — |
| Non-GAAP Adjusted EBITDA per common share - Diluted non-GAAP | $0.1 | Year ended December 31, 2025 | — |
| Payer access for Emrosi™ - U.S. commercial lives | 100M | July 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DERM
this stock
Journey Medical Corp
|
$210.84M | -3.1% | +10.2% | — | 10.3% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.59B | +15.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.38B | +2.2% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.46B | +0.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DERM | -3.6% | +17.3% | -6.9% | +17.3% | -3.1% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -4.1% | +14.3% | -20.3% | +14.3% | -15.9% |
Key facts
CIK
1867066
CUSIP
48115J109
13F (30d)
66 filings
64 filers
Visit website
Investor relations